GlaxoSmithKline Pharmaceuticals has reported a 1.29 per cent rise in its net profit at Rs 138.51 crore for the quarter ended December 31, 2012.
The company had posted a net profit of Rs 136.74 crore in the corresponding period previous fiscal, the it said in a statement.
Net sales stood at Rs 656.69 crore against Rs 566.03 crore.
In a separate statement, the company said its board has recommended a dividend of Rs 50 per equity share for the year.
“If approved by the shareholders at the annual general meeting, the dividend will absorb Rs 424 crore. The dividend distribution tax borne by the company will amount to Rs 64 crore,” GlaxoSmithKline Pharmaceuticals said.
In 2012, the company added new products across various therapeutic areas.
Altargo was launched in the dermatology portfolio, Volibris was launched to treat pulmonary arterial hypertension and Hycamtin was launched to fulfil the unmet needs of patients with advance cancer and relapsed small cell lung cancer, the company said.
Shares of GlaxoSmithKline Pharmaceuticals were trading at Rs 2,104.45 per scrip, up 0.62 per cent on the BSE today.